UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063679
Receipt number R000072869
Scientific Title A Study on the Usability and Efficacy of a Novel Skincare Technology
Date of disclosure of the study information 2026/11/18
Last modified on 2026/11/18 15:13:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Study on the Usability and Efficacy of a Novel Skincare Technology

Acronym

A Study on the Usability and Efficacy of a Novel Skincare Technology

Scientific Title

A Study on the Usability and Efficacy of a Novel Skincare Technology

Scientific Title:Acronym

A Study on the Usability and Efficacy of a Novel Skincare Technology

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The efficacy and usability of a novel skincare technology will be evaluated by assessing its effects on skin condition and user perception.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Changes in stratum corneum hydration, transepidermal water loss (TEWL), and skin appearance at 7 days after use of the investigational product and 7 days after switching to the control products.

Key secondary outcomes

Assessment of usability and perceived efficacy after 7 days of use of the investigational skincare technology and 7 days after switching to the control skincare products.


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

NO

Concealment

Pseudo-randomization


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

A novel skincare technology (FQW071W1) will be applied to one cheek for 7 days after application of a control lotion (right cheek for participants with even-numbered IDs and left cheek for those with odd-numbered IDs). Thereafter, all participants will apply the control products (control lotion and control emulsion) to both cheeks for 7 days.

Interventions/Control_2

As a comparator, a moisturizing cream will be applied to the contralateral cheek for 7 days after application of a control lotion (left cheek for participants with even-numbered IDs and right cheek for those with odd-numbered IDs). Thereafter, all participants will apply the control products (control lotion and control emulsion) to both cheeks for 7 days.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >=

Gender

Female

Key inclusion criteria

1) Healthy females aged 20 to 60 years at the time of informed consent.
2) Individuals who have concerns about facial skin dryness and subjectively experience dry skin symptoms such as flaking, scaling, or skin roughness on the cheek area.
3) Individuals who either show signs of dryness on the cheek area as assessed by visual examination by the study staff, or whose cheek skin exhibits a tendency toward dryness as confirmed by instrumental assessment.
4) Individuals who are able to attend the scheduled study visits and undergo all required examinations.
5) Individuals who are considered eligible for participation in this study by the principal investigator.

Key exclusion criteria

1) Individuals with severe atopic dermatitis or other skin diseases.
2) Individuals with a history of allergy to cosmetics or medications.
3) Individuals who are pregnant, may be pregnant, or are breastfeeding.
4) Individuals with a current or past history of serious cardiac, hepatic, renal, or cardiovascular disease.
5) Individuals who are currently receiving, or have received within the past 3 months, treatments that may affect skin function (e.g., chemical peeling, laser treatment, or use of prescription medications).
6) Individuals receiving hormone replacement therapy.
7) Individuals who have participated in another clinical trial or interventional study within the past 3 months.
8) Individuals with significant skin abnormalities, such as large wounds, eruptions, or warts, at the assessment site.
9) Individuals deemed unsuitable for participation in this study by the principal investigator or study staff.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Hideki
Middle name
Last name Miwake

Organization

FANCL Corporation

Division name

Research Institute

Zip code

244-0806

Address

12-13, Kamishinano, Totsuka-ku, Yokohama, Kanagawa

TEL

045-820-3696

Email

miwake_hideki@fancl.co.jp


Public contact

Name of contact person

1st name Yoko
Middle name
Last name Imai

Organization

FANCL Corporation

Division name

Research Institute

Zip code

2440806

Address

12-13, Kamishinano, Totsuka-ku, Yokohama, Kanagawa

TEL

0458203539

Homepage URL


Email

yoko1607@fancl.co.jp


Sponsor or person

Institute

FANCL Corporation

Institute

Department

Personal name

Yoko Imai


Funding Source

Organization

FANCL Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

FANCL Corporation Ethics Committee

Address

12-13 Kamishinano, Yokohama Totsuka-ku, Kanagawa

Tel

045-226-1375

Email

hitomi@fancl.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 10 Month 21 Day

Date of IRB


Anticipated trial start date

2026 Year 11 Month 18 Day

Last follow-up date

2027 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 11 Month 18 Day

Last modified on

2026 Year 11 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072869